Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Trademarks
Novartis India has agreed to acquire Pfizer's 'Minipress' and 'Minipres' trademarks in India for INR 1,250 crore. Meanwhile, Pfizer Ltd announced it will discontinue the marketing and sale of Minipress XL following a global manufacturing halt by Pfizer Inc. Minipress XL is prescribed in India primarily for treating hypertension or high blood pressure.
Novartis India Ltd today, September 7, announced that its board of directors has approved the acquisition of the trademarks "Minipress" and "Minipres" from Pfizer Inc. USA and Pfizer Products Inc. USA for a total consideration of INR 1,250 crore.
Acquisition Details and Agreements
In a regulatory filing, Novartis India stated that the transaction involves purchasing trademarks registered in India alongside specific related intellectual property rights. Novartis Layoffs: Drugmaker To Cut 130 Jobs in Switzerland Amid Biologics Rework.
Novartis India has executed an asset purchase agreement and trademark assignment deeds with the US-based entities, with the signing and closing of the transaction scheduled to take place simultaneously.
Market Performance and Usage
Minipress XL, which contains the active pharmaceutical ingredient prazosin, is prescribed in India primarily for treating hypertension, or high blood pressure, as well as managing urinary symptoms associated with benign prostatic hyperplasia (BPH). According to IQVIA MAT data for July 2026, Minipress XL recorded revenues of INR 228.6 crore. The brand has maintained a compound annual growth rate (CAGR) of 6.3 per cent over the past four years.
Pfizer Operations Update
In a separate regulatory filing, Pfizer Ltd announced that it will discontinue the marketing, distribution, and sale of Minipress XL. The company stated that this decision follows a directive by Pfizer Inc. USA to stop the manufacturing of Minipress XL.
(The above story first appeared on LatestLY on Sep 07, 2026 02:40 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
